## NSC 107512

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-141687 22242-89-3 C <sub>12</sub> H <sub>16</sub> N <sub>6</sub> O <sub>5</sub> 324.29 CDK; Apoptosis Cell Cycle/DNA Damage; Apoptosis -20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)	OH HOM H <sup>W</sup> OOH
	nitrogen)	OIT

## SOLVENT & SOLUBILITY

In Vitro		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	3.0837 mL	15.4183 mL	30.8366 mL		
		5 mM	0.6167 mL	3.0837 mL	6.1673 mL		
		10 mM	0.3084 mL	1.5418 mL	3.0837 mL		
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.					
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 4.25 mg/mL (13.11 mM); Clear solution					
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 4.25 mg/mL (13.11 mM); Clear solution					
		3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 4.25 mg/mL (13.11 mM); Clear solution					

BIOLOGICAL ACTIVITY				
Description	NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors <sup>[1]</sup> .			
IC <sub>50</sub> & Target	CDK9 <sup>[1]</sup>			

## REFERENCES



[1]. Dolloff NG, et al. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012;11(11):2321-2330.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA